Video Experimental Relacionado
Updated: Jul 22, 2026
10:33
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Inhibidores de dos puntas para la anhidrase carbónica humana II en el hombre
Bidhan C Roy1, Abir L Banerjee, Michael Swanson
1Department of Chemistry, Biochemistry & Molecular Biology, North Dakota State University, Fargo, North Dakota 58105, USA.
Journal of the American Chemical Society
|October 14, 2004
Resumen
Los investigadores desarrollaron una nueva estrategia de "dos puntas" para mejorar la afinidad de unión del inhibidor de la enzima. Al agregar grupos de sujeción que interactúan con los residuos superficiales, mejoraron significativamente la potencia inhibidora contra la anhidrase carbónica humana II.
Área de la Ciencia:
- Química medicinal Química medicinal es el campo de la química medicinal.
- Diseño del inhibidor de enzimas.
- La bioquímica es la bioquímica.
Sus antecedentes:
- El diseño convencional de inhibidores de enzimas se centra en los bolsillos del sitio activo, a menudo produciendo afinidades de unión subóptimas.
- Mejorar la afinidad del inhibidor es crucial para desarrollar terapias efectivas.
Objetivo del estudio:
- Introducir una nueva estrategia para mejorar la afinidad de unión de inhibidores de enzimas.
- Para convertir los inhibidores débiles de las enzimas en inhibidores de unión estrecha utilizando un enfoque de "dos puntas".
Principales métodos:
- Diseño de inhibidores con grupos de sujeción para interactuar con los residuos de aminoácidos expuestos en la superficie.
- Prueba de la estrategia para la inhibición de la anhidrasa carbónica humana II.
- Conjugando un inhibidor débil (benzenesulfonamida) con iminodiacetato-Cu2+ a través de un grupo espaciador.
Principales resultados:
- El enfoque de "dos puntas" mejoró significativamente la afinidad de unión de la benzenesulfonamida para la anhidrasa carbónica humana II.
- La afinidad de unión se mejoró en aproximadamente dos órdenes de magnitud.
- El inhibidor atado demostró una potente interacción con los residuos de histidina expuestos en la superficie.
Conclusiones:
- La estrategia de "dos puntas" desarrollada mejora efectivamente la afinidad de unión al inhibidor.
- Este enfoque ofrece un método generalizable para convertir inhibidores débiles en potentes.
- La estrategia es prometedora para el desarrollo de nuevas terapias dirigidas a las enzimas.
Videos de Conceptos Relacionados
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...